• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

波兰呼吸学会特发性肺纤维化诊断和治疗指南。

Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary fibrosis.

机构信息

Department of Pneumology and Allergy, Medical University of Lodz, Lodz, Poland.

Department of Radiology, National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland.

出版信息

Adv Respir Med. 2020;88(1):41-93. doi: 10.5603/ARM.2020.0081.

DOI:10.5603/ARM.2020.0081
PMID:32153010
Abstract

INTRODUCTION

This document presents the guidelines of the Polish Respiratory Society (PTChP, Polskie Towarzystwo Chorób Płuc) for diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), developed by agroup of Polish experts.

MATERIAL AND METHODS

The recommendations were developed in the form of answers to previously formulated questions concer-ning everyday diagnostic and therapeutic challenges. They were developed based on acurrent literature review using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology.

RESULTS

We formulated 28 recommendations for diagnosis (8), pharmacological treatment (12) as well as non-pharma-cological and palliative therapy (8). The experts suggest that surgical lung biopsy (SLB) not be performed in patients with the probable usual interstitial pneumonia (UIP) pattern, with an appropriate clinical context and unanimous opinion of a multidisciplinary team. The experts recommend using antifibrotic agents in IPF patients and suggest their use irrespective of the degree of functional impairment. As regards non-pharmacological and palliative treatment, strong re-commendations were formulated regarding pulmonary rehabilitation, oxygen therapy (in patients with chronic respiratory failure), preventive vaccinations as well as referring IPF patients to transplant centres. Table 1 presents an aggregate list of recommendations.

CONCLUSIONS

The Polish Respiratory Society Working Group developed guidelines for IPF diagnosis and treatment.

摘要

简介

本文介绍了波兰呼吸学会(PTChP,Polskie Towarzystwo Chorób Płuc)制定的特发性肺纤维化(IPF)诊断和治疗指南,由一组波兰专家编写。

材料和方法

本指南以回答日常诊断和治疗挑战相关问题的形式呈现,采用当前文献综述,并使用推荐评估、制定与评价分级(GRADE)方法。

结果

我们制定了 28 条诊断(8 条)、药物治疗(12 条)以及非药物和姑息治疗(8 条)建议。专家建议,对于可能为普通型间质性肺炎(UIP)模式、具有适当临床背景且多学科团队意见一致的患者,不进行外科肺活检(SLB)。专家建议在 IPF 患者中使用抗纤维化药物,并建议无论功能损害程度如何都应使用。关于非药物和姑息治疗,强烈建议进行肺康复、氧疗(慢性呼吸衰竭患者)、预防接种,并将 IPF 患者转至移植中心。表 1 列出了汇总的建议清单。

结论

波兰呼吸学会工作组制定了 IPF 诊断和治疗指南。

相似文献

1
Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary fibrosis.波兰呼吸学会特发性肺纤维化诊断和治疗指南。
Adv Respir Med. 2020;88(1):41-93. doi: 10.5603/ARM.2020.0081.
2
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.特发性肺纤维化诊断。美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会临床实践指南。
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.
3
Diagnostic and treatment standards in idiopathic pulmonary fibrosis in the era of antifibrotic drugs in Poland: A real-world practice survey.波兰抗纤维化药物时代特发性肺纤维化的诊断与治疗标准:一项真实世界实践调查。
Adv Respir Med. 2019;87(6):221-230. doi: 10.5603/ARM.2019.0060.
4
Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis.波兰呼吸学会关于非特发性肺纤维化的进行性纤维性间质性肺疾病的诊断和治疗指南。
Adv Respir Med. 2022 Oct 4;90(5):425-450. doi: 10.3390/arm90050052.
5
Translating Idiopathic pulmonary fibrosis guidelines into clinical practice.将特发性肺纤维化指南转化为临床实践。
Pulmonology. 2021 Jan-Feb;27(1):7-13. doi: 10.1016/j.pulmoe.2020.05.017. Epub 2020 Jun 16.
6
[Polish respiratory society guidelines for chronic obstructive pulmonary disease].[波兰呼吸学会慢性阻塞性肺疾病指南]
Pneumonol Alergol Pol. 2014;82(3):227-63. doi: 10.5603/PiAP.2014.0030.
7
Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.定义特发性肺纤维化明确诊断的诊断似然阈值。
Am J Respir Crit Care Med. 2019 Nov 1;200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.
8
Interobserver Agreement of Usual Interstitial Pneumonia Diagnosis Correlated With Patient Outcome.普通间质性肺炎诊断的观察者间一致性与患者预后的相关性
Arch Pathol Lab Med. 2016 Dec;140(12):1375-1382. doi: 10.5858/arpa.2016-0012-OA. Epub 2016 Sep 9.
9
Idiopathic pulmonary fibrosis (IPF) - common practice in Poland before the "antifibrotic drugs era".特发性肺纤维化(IPF)——“抗纤维化药物时代”之前波兰的常见做法。
Adv Respir Med. 2017;85(3):136-142. doi: 10.5603/ARM.2017.0023.
10
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.特发性肺纤维化的诊断标准:弗利彻协会白皮书。
Lancet Respir Med. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15.

引用本文的文献

1
Concomitant Idiopathic Pulmonary Fibrosis and Lung Cancer: An Updated Narrative Review.特发性肺纤维化与肺癌并存:最新叙述性综述
Adv Respir Med. 2025 Aug 18;93(4):31. doi: 10.3390/arm93040031.
2
Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a analysis of two multicenter observational cohort studies in Poland.特发性肺纤维化患者抗纤维化治疗的真实世界治疗持续性及停药预测因素:波兰两项多中心观察性队列研究的分析
Front Pharmacol. 2025 Jun 5;16:1586197. doi: 10.3389/fphar.2025.1586197. eCollection 2025.
3
Polymorphism in Patients with Idiopathic Pulmonary Fibrosis-Does It Really Matter?
特发性肺纤维化患者的多态性——真的重要吗?
Int J Mol Sci. 2025 Feb 28;26(5):2218. doi: 10.3390/ijms26052218.
4
Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects.基于人脐带间充质干细胞的方法在肺部疾病中的治疗效用:最新进展与前景
World J Stem Cells. 2024 Feb 26;16(2):70-88. doi: 10.4252/wjsc.v16.i2.70.
5
Acute exacerbation of idiopathic pulmonary fibrosis after bivalent {tozinameran and famtozinameran} mRNA COVID-19 vaccination.二价{托珠单抗和法莫珠单抗} mRNA新冠疫苗接种后特发性肺纤维化急性加重
Respir Med Case Rep. 2023 Dec 9;46:101960. doi: 10.1016/j.rmcr.2023.101960. eCollection 2023.
6
Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single-arm, open-label nonrandomized study.特发性肺纤维化患者使用吡非尼酮治疗1年前后的期望、症状及生活质量:一项单臂、开放标签的非随机研究。
Health Sci Rep. 2023 Aug 16;6(8):e1449. doi: 10.1002/hsr2.1449. eCollection 2023 Aug.
7
Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline.慢性呼吸疾病成人的肺康复:美国胸科学会临床实践指南
Am J Respir Crit Care Med. 2023 Aug 15;208(4):e7-e26. doi: 10.1164/rccm.202306-1066ST.
8
A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study.一项关于尼达尼布治疗特发性肺纤维化患者的波兰经验的真实世界多中心回顾性观察研究:PolExNIB研究。
J Clin Med. 2023 Jul 12;12(14):4635. doi: 10.3390/jcm12144635.
9
Bronchoalveolar Lavage Cell Count and Lymphocytosis Are the Important Discriminators between Fibrotic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis.支气管肺泡灌洗细胞计数和淋巴细胞增多是纤维化性过敏性肺炎与特发性肺纤维化之间的重要鉴别指标。
Diagnostics (Basel). 2023 Mar 1;13(5):935. doi: 10.3390/diagnostics13050935.
10
Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis.波兰呼吸学会关于非特发性肺纤维化的进行性纤维性间质性肺疾病的诊断和治疗指南。
Adv Respir Med. 2022 Oct 4;90(5):425-450. doi: 10.3390/arm90050052.